Recent

% | $
Quotes you view appear here for quick access.

Cyclacel Pharmaceuticals, Inc. Message Board

  • mastino88 mastino88 Feb 12, 2013 7:12 AM Flag

    New patents granted: now CELG wants us even more

     

    The two patents include claims to combinations of sapacitabine and HDAC inhibitors, pharmaceutical compositions comprising sapacitabine and HDAC inhibitors, and methods of treatment using such compositions of proliferative disorders including leukemias, lymphomas, and lung cancer. HDAC inhibitors specifically claimed include belinostat (PXD101), dacinostat (LAQ824), entinostat (MS-275), mocetinostat (MGCD0103), pracinostat (SB939), romidepsin (depsipeptide), sodium butyrate, sodium valproate, tacedinaline (CI-994, PD-123654, GOE-5549, acetyldinaline), trichostatin A, vorinostat (SAHA or suberoylanilide hydramic acid), and valproic acid. Cyclacel published preclinical model data in 2010 demonstrating that sapacitabine works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in vitro and in vivo.

    The claims and specifications of the '792 and '790 patents are unrelated to the claims and specifications of the four Cyclacel-owned patents that are the subject of Cyclacel's intellectual property litigation with Celgene Corporation (Celgene) regarding Celgene's drug romidepsin (depsipeptide, Istodax).

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CYCC
0.560.00(+0.18%)Aug 31 3:59 PMEDT